Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analysts have given Halozyme Therapeutics an average recommendation of "Hold", with ratings varying from two sell ratings to one strong buy rating.
• Halozyme reported a 40.8% increase in revenue for the last quarter compared to the previous year, earning $1.54 per share, exceeding estimates by $0.31.
• Insider trading activity includes significant stock sales by CEO Helen Torley and CFO Nicole Labrosse in September, with total sales exceeding $3 million.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has been given an average recommendation of "Hold" by the twelve brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $67.1111.

Several research analysts have issued reports on HALO shares. HC Wainwright increased their price objective on Halozyme Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. JMP Securities increased their price objective on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. Morgan Stanley increased their price objective on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research report on Monday, August 18th. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price on the stock. Finally, JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th.

Halozyme Therapeutics Trading Up 1.5%

NASDAQ:HALO opened at $77.81 on Friday. The stock has a fifty day moving average price of $67.13 and a two-hundred day moving average price of $61.08. The stock has a market capitalization of $9.10 billion, a price-to-earnings ratio of 17.81, a PEG ratio of 0.42 and a beta of 1.19. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics has a 1 year low of $42.01 and a 1 year high of $77.95.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, sell-side analysts anticipate that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $74.44, for a total value of $1,488,800.00. Following the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $54,618,042.36. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Nicole Labrosse sold 20,000 shares of the company's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00. Following the completion of the sale, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This trade represents a 45.14% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 104,000 shares of company stock valued at $6,771,120. Insiders own 2.40% of the company's stock.

Institutional Trading of Halozyme Therapeutics

Large investors have recently made changes to their positions in the stock. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at $29,000. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at $32,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics during the first quarter valued at $33,000. Finally, Bessemer Group Inc. boosted its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.